Cost-effectiveness analysis alongside clinical trials II - An ISPOR good research practices task force report

Value in Health

Volumn 18, Issue 2, 2015, Pages 161-172

  Ramsey, Scott D ^a,b   Willke, Richard J ^c   Glick, Henry ^d   Reed, Shelby D ^e   Augustovski, Federico ^f   Jonsson, Bengt ^g   Briggs, Andrew ^h   Sullivan, Sean D ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^g STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

clinical trial; cost effectiveness; economic; guidelines

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EXTERNAL VALIDITY; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE ALLOCATION; STANDARD; STUDY DESIGN; ADVISORY COMMITTEE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE POLICY; HEALTH SERVICES RESEARCH; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH;

ADVISORY COMMITTEES; COST-BENEFIT ANALYSIS; HEALTH POLICY; HEALTH SERVICES RESEARCH; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH REPORT;

EID: 84924857556     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2015.02.001     Document Type: Article

References (171)

1. M. Berntgen, A. Gourvil, and M. Pavlovic Improving the contribution of regulatory assessment reports to health technology assessments - a collaboration between the European Medicines Agency and the European Network for Health Technology Assessment Value Health 15 2014 634 641
2. B. Jönsson Relative effectiveness and the European pharmaceutical market Eur J Health Econ 12 2011 97 102
3. B.R. Luce, M.F. Drummond, and R.W. Dubois Principles for planning and conducting comparative effectiveness research J Comp Eff Res 1 2012 431 440
4. M.S. Lauer, and R.B. D'Agostino Sr The randomized registry trial - the next disruptive technology in clinical research? N Engl J Med 369 2013 1579 1581
5. S.D. Ramsey, R.J. Willke, and A.H. Briggs Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report Value Health 8 2005 521 533
6. M.R. Gold, J.E. Siegel, L.B. Russell, and M. Weinstein Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
7. EUnetHTA. HTA Core Model® for rapid relative effectiveness assessment of pharmaceuticals. Available from: http://www.eunethta.eu/outputs/new-application-hta-core-model-hta-core-model-rapid-relative-effectiveness-assessment-pharma. [Accessed December 19, 2014].
8. D. Schwartz, and J. Lellouch Explanatory and pragmatic attitudes in therapeutical trials J Chronic Dis 20 1967 637 648
9. B. O'Brien Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire of trials? Med Care 34 1996 DS99 108
10. M.J. Schulpher, K. Claxton, M. Drummond, and C. McCabe Whither trial-based economic evaluations for health care decision making? Health Econ 15 2006 677 687
11. M.E. Backhouse, M. Wonder, and E. Hornby Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study Value Health 14 2011 608 615
12. Haute Autorite de Sante. Shaping European Early Dialogues for health technologies (SEED). Available from: http://www.has-sante.fr/portail/jcms/c-1700958/fr/seed-shaping-european-early-dialogues-for-health-technologies. [Accessed December 19, 2014].
13. European Medicines Agency-EUnetHTA. EMA-EUnetHTA three-year work plan 2013-2015. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Other/2013/11/WC500154588.pdf. [Accessed December 19, 2014].
14. H.-G. Eichler, B. Bloechl-Daum, and E. Abadieet Relative efficacy of drugs: an emerging issue between regulatory agencies and third party payers Nat Rev Drug Discovery 9 2010 277 291
15. M.F. Drummond, M.J. Sculpher, and G.W. Torrance Methods for the Economic Evaluation of Health Care Programmes 3rd ed. 2005 Oxford University Press Oxford
16. B.J. O'Brien A tale of two or more cities: geographic transferability of pharmacoeconomic data Am J Man Care 3 1997 S33 S39
17. K. Schulman, J. Burke, and M. Drummond Resource costing for multinational neurologic clinical trials: methods and results Health Econ 7 1998 629 638
18. M.A. Koopmanschap, K.C.R. Touw, and FFH. Rutten Analysis of costs and cost-effectiveness in multinational trials Health Policy 58 2001 175 186
19. T.B. Gosden, and D.J. Torgerson Converting international cost-effectiveness data to UK prices BMJ 325 2002 275 276
20. S.D. Sullivan, B. Liljas, and M.J. Buxton Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial Control Clin Trials 22 2001 420 437
21. M.J. Buxton, S.D. Sullivan, and F.L. Andersson Country-specific cost-effectiveness of early intervention with budesonide in mild asthma Eur Respir J 24 2004 568 574
22. U.G. Gerdtham, and B. Jönsson Conversion factor instability in international comparisons of health care expenditure J Health Econ 10 1991 227 234
23. World Bank. World Development Indicators 2001. Washington, DC: The World Bank, 2001.
24. Eureopean Medicines Agency. Guideline on the investigation of subgroups in 4 confirmatory clinical trials, EMA/CHMP/539146/2013. 2014. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/02/WC500160523.pdf. [Accessed December 19, 2014].
25. A.H. Briggs, H.A. Glick, and G. Lozano-Ortega Towards a revolution in COPD health (TORCH) investigators. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Eur Respir J 35 2010 532 539
26. S.D. Sullivan, M. Buxton, and L.F. Andersson Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma J Allergy Clin Immunol 112 2003 1229 1236
27. W.S. Weintraub, Z. Zhang, and E.M. Mahoney Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure Circulation 111 2005 1106 1113
28. M. Drummond, M. Barbieri, and J. Cook Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report Value Health 12 2009 409 418
29. E.M. Pinto, A.R. Willan, and B.J. O'Brien Cost-effectiveness analysis for multinational clinical trials Stat Med 24 2005 1965 1982
30. E.M. Laska, M. Meisner, and C. Siegel Power and sample size in cost-effectiveness analysis Med Decis Making 19 1999 339 343
31. A. Briggs, and M. Tambour The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions Drug Inf J 35 2001 1455 1468
32. B.J. Koerkamp, S. Spronk, T. Stijnen, and M.G.M. Hunink Value of information analyses and economic randomized controlled trials: the treatment of intermittent claudication Value Health 13 2010 242 250
33. A.R. Willan, and S. Eckermann Optimal clinical trial design using value of information methods with imperfect information Health Econ 19 2010 549 561
34. M.J. Al, B. van Hout, and B.C. Michel Sample size calculation in economic evaluations Health Econ 7 1998 327 335
35. M.J. Gardner, and D.G. Altman Estimation rather than hypothesis testing: confidence intervals rather than P values M.J. Gardner, D.G. Altman, Statistics with Confidence 1989 BMJ London
36. K. Claxton, and J. Posnett An economic approach to clinical trial design and research priority setting Health Econ 5 1996 513 524
37. A.R. Willan, and E.M. Pinto The expected value of information and optimal clinical trial design Stat Med 24 2005 1791 1806
38. A.R. Willan Optimal sample size determinations from an industry perspective based on the expected value of information Clin Trials 5 2008 587 594
39. J.A. Cooke, J. Hislop, and T.E. Adewuyi Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review Health Technol Assess 2014 18
40. EUnetHTA. GUIDELINE - endpoints used for relative effectiveness assessment of pharmaceuticals: CLINICAL ENDPOINTS. 2013. Available from: http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Clinical%20endpoints.pdf. [Accessed December 19, 2014].
41. A. Bhandari, and T. Wagner Self-reported utilization of health care services: improving measurement and accuracy Med Care Res Rev 63 2006 217 235
42. C. Evans, and B. Crawford Patient self-reports in pharmacoeconomic studies Pharmacoeconomics 15 1999 241 256
43. A. Manca, N. Hawkins, and M.J. Sculpher Estimating mean QALYS in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility Health Econ 14 2005 487 496
44. H.A. Glick, J.A. Doshi, S.S. Sonnad, and D. Polsky Economic Evaluation in Clinical Trials 2nd ed. 2015 Oxford University Press New York
45. K. Claxton The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies J Health Econ 18 1999 341 364
46. A.E. Ades, G. Lu, and K. Claxton Expected value of sample information calculations in medical decision modeling Med Decis Making 24 2004 207 227
47. M.E. Goossens, M.P. Rutten-van Mölken, and J.W. Vlaeyen The cost diary: a method to measure direct and indirect costs in cost-effectiveness research J Clin Epidemiol 53 2000 688 695
48. N. Chernyak, C. Ernsting, and A. Icks Pre-test of questions on health-related resource use and expenditure, using behaviour coding and cognitive interviewing techniques BMC Health Serv Res 12 2012 303
49. K. Tang Estimating productivity costs in health economic evaluations: a review of instruments and psychometric evidence Pharmacoeconomics 33 2015 31 48
50. DIRUM. Database of Instruments for Resource Use Measurement. Available from: http://www.dirum.org. [Accessed July 31, 2014].
51. C.H. Ridyard, D.A. Hughes DIRUM Team. Development of a database of instruments for resource-use measurement: purpose, feasibility, and design Value Health 15 2012 650 655
52. M.C. Reilly, A.S. Zrobzek, and E.M. Dukes The validity and reproducibility of a work productivity and activity impairment instrument Pharmacoeconomics 4 1993 353 365
53. D. Lerner, B.C. Amick III, and W.H. Rogers The work limitations questionnaire Med Care 39 2001 72 85
54. M. Prasad, P. Wahlquist, and R. Shikiar A review of self-report instruments measuring health-related work productivity Pharmacoeconomics 22 2004 225 244
55. P. Dolan Modelling valuations in EuroQol health states Med Care 35 1997 1095 1108
56. M.F. Janssen, A.S. Pickard, and D. Golicki Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study Qual Life Res 22 2013 1717 1727
57. M. Herdman, C. Gudex, and A. Lloyd Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res 20 2011 1727 1736
58. G.W. Torrance, D.H. Feeny, and W.J. Furlong Multi-attribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2 Med Care 34 1996 702 722
59. G.W. Torrance, M.H. Boyle, and S.P. Horwood Application of multi-attribute utility theory to measure social preferences for health states Oper Res 30 1982 1043 1069
60. D. Feeny, W. Furlong, and G.W. Torrance Multi-attribute and single-attribute utility functions for the health utilities index mark 3 system Med Care 40 2002 113 128
61. R.M. Kaplan, and J.P. Anderson A general health policy model: update and applications Health Serv Res 23 1988 203 235
62. R.M. Kaplan, and J.P. Anderson The general health policy model: an integrated approach B. Spiker, Quality of Life and Pharmacoeconomics in Clinical Trials 1996 Lippincott-Raven Philadelphia
63. J. Brazier, J. Roberts, and M. Deverill The estimation of a preference-based measure of health from the SF-36 J Health Econ 21 2002 271 292
64. B.M. Craig, A.S. Pickard, and E. Stolk US valuation of the SF-6D Med Decis Making 33 2013 793 803
65. J. Richardson, A. Iezzi, M.A. Khan, and A. Maxwell Validity and reliability of the Assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument Patient 7 2014 85 96
66. J.E. Brazier, Y. Yang, and A. Tsuchiya A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures Eur J Health Econ 11 2010 215 225
67. D. Mortimer, and L. Segal Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights Med Decis Making 28 2008 66 89
68. M. Hernández Alava, A. Wailoo, and F. Wolfe A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes Med Decis Making 34 2013 919 930
69. P.M. Fayers, and R.D. Hays Should linking replace regression when mapping from profile-based measures to preference-based measures? Value Health 17 2014 261 265
70. K.K. Chan, A.R. Willan, and M. Gupta Underestimation of uncertainties in health utilities derived from mapping algorithms involving health-related quality-of-life measures: statistical explanations and potential remedies Med Decis Making 34 2014 863 872
71. L.-H. Chuang, and S.J. Whitehead Mapping for economic evaluation Br Med Bull 101 2012 1 15
72. H. McTaggart-Cowan, P. Teckle, and S. Peacock Mapping utilities from cancer-specific health-related quality of life instruments: a review of the literature Expert Rev Pharmacoecon Outcomes Res 13 2013 753 765
73. R. Norman, R. Viney, and J. Brazier Valuing SF-6D health states using a discrete choice experiment Med Decis Making 34 2013 773 786
74. N. Bansback, J. Brazier, and A. Tsuchiya Using a discrete choice experiment to estimate health state utility values J Health Econ 31 2012 306 318
75. M. Barbieri, M. Drummond, and F. Rutten ISPOR Good Research Practices Economic Data Transferability Task Force What do international pharmacoeconomic guidelines say about economic data transferability? Value Health 13 2010 1028 1037
76. Marcano Belisario JS, Huckvale K, Saje A, et al. Comparison of self administered survey questionnaire responses collected using mobile apps versus other methods. The Cochrane Library 2014;Issue 4. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.MR000042/abstract. [Accessed July 31, 2014].
77. S.J. Coons, C.J. Gwaltney, and R.D. Hays Recommendations on evidence needed to support measurement equivalence between electronic and paper based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report Value Health 12 2009 419 429
78. A. Bowling Mode of questionnaire administration can have serious effects on data quality J Pub Health 27 2005 281 291
79. P. Vemer, and M.P. Rutten-van Mölken The road not taken: transferability issues in multinational trials Pharmacoeconomics 31 2013 863 876
80. J.W. Hay, J. Smeeding, and N.V. Carroll Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report - part I Value Health 13 2010 3 7
81. K. Johnston, M.J. Buxton, D.R. Jones, and R. Fitzpatrick Assessing the costs of healthcare technologies in clinical trials Health Technol Assess 3 1999 1 76
82. F. Cots, D. Elvira, and X. Castells Medicare's DRG-weights in a European environment: the Spanish experience Health Policy 51 2000 31 47
83. W. Quentin, H. Rätto, M. Peltola EuroDRG group Acute myocardial infarction and diagnosis-related groups: patient classification and hospital reimbursement in 11 European countries Eur Heart J 34 2013 1972 1981
84. B.R. Luce, W.G. Manning, and J.E. Siegel Report of the Panel on Cost-Effectiveness in Health and Medicine M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein, Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York, NY
85. L.H. Curtis, J. Brown, and R. Platt Four health data networks illustrate the potential for a shared national multipurpose big-data network Health Aff (Millwood) 33 2014 1178 1186
86. J.C. Maro, R. Platt, and J.H. Holmes Design of a national distributed health data network Ann Intern Med 151 2009 341 344
87. S.D. Ramsey, S.D. Sullivan, and R.M. Kaplan Economic analysis of lung volume reduction surgery as part of the National Emphysema Treatment Trial. NETT Research Group Ann Thorac Surg 71 2001 995 1002
88. S.D. Sullivan, B. Liljas, M. Buxton START Steering Committee Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial Control Clin Trials 22 2001 420 437
89. J.A. Spertus, J. Tooley, and P. Jones Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study) Am Heart J 143 2002 637 642
90. J.A. Barber, and S.G. Thompson Analysis and interpretation of cost data in randomised controlled trials: review of published studies BMJ 317 1998 1195 1200
91. A. O'Hagan, and J.W. Stevens Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality? Health Econ 12 2003 33 49
92. S.G. Thompson, and J.A. Barber How should cost data in pragmatic randomised trials be analysed? BMJ 320 2000 1197 1199
93. A. Briggs, and A. Gray The distribution of health care costs and their statistical analysis for economic evaluation J Health Serv Res Policy 3 1998 233 245
94. B. Efron, and R. Tibshirani An Introduction to the Bootstrap 1993 Chapman and Hall New York
95. A. Desgagne, A.M. Castilloux, and J.F. Angers The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data Pharmacoeconomics 13 1998 487 497
96. J.A. Barber, and S.G. Thomson Analysis of cost data in randomized trials: an application of the nonparametric bootstrap Stat Med 19 2000 3219 3236
97. M. Gomes, E.S.W. Ng, and R.D. Grieve Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials Med Decis Making 32 2012 350 361
98. R.M. Nixon, D. Wonderling, and R.D. Grieve Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared Health Econ 19 2010 316 333
99. A.H. Briggs, and A.M. Gray Handling uncertainty when performing economic evaluation of health care interventions Health Technol Assess 3 1999 1 134
100. J.A. Barber, and S.G. Thompson Analysis of cost data in randomized trials: an application of the nonparametric bootstrap Stat Med 19 2000 3219 3236
101. A. Briggs, P. Clarke, and D. Polsky Modelling the cost of health care interventions. Paper prepared for DEEM III: Costing Methods for Economic Evaluation University of Aberdeen April 15-16, 2003
102. W.G. Manning The logged dependent variable, heteroscedasticity, and the retransformation problem J Health Econ 17 1998 283 295
103. W.G. Manning, and J. Mullahy Estimating log models: to transform or not to transform? J Health Econ 20 2001 461 494
104. J.M. Bland, and D.G. Altman The use of transformation when comparing two means BMJ 312 1996 1153
105. J.M. Bland, and D.G. Altman Transformations, means, and confidence intervals BMJ 312 1996 1079
106. J.M. Bland, and D.G. Altman Transforming data BMJ 312 1996 770
107. I.R. White, and S.G. Thompson Choice of test for comparing two groups, with particular application to skewed outcomes Stat Med 22 2003 1205 1215
108. D.K. Blough, C.W. Madden, and M.C. Hornbrook Modeling risk using generalized linear models J Health Econ 18 1999 153 171
109. D.L. Patrick, and P. Erickson Ranking costs and outcomes of health care alternatives Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation 1993 Oxford University Press New York
110. A. Basu, and P.J. Rathouz Estimating marginal and incremental effects on health outcomes using flexible link and variance function models Biostat 6 2005 93 109
111. M. Hernandez Alava, A.J. Wailoo, and R. Ara Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values Value Health 15 2012 550 561
112. P.C. Austin A comparison of methods for analyzing health-related quality of life measures Value Health 4 2002 329 337
113. S.M. Gray, and R. Brookmeyer Estimating a treatment effect from multidimensional longitudinal data Biometrics 54 1998 976 988
114. D. Hedeker, and R.D. Gibbons Application of random effects pattern-mixture models for missing data in longitudinal studies Pyschol Methods 2 1997 64 78
115. A.H. Briggs, and B.J. O'Brien The death of cost-minimization analysis? Health Econ 10 2001 179 184
116. H. Dakin, and S. Wordsworth Cost-minimisation analysis versus cost-effectiveness analysis, revisited Health Econ 22 2013 22 34
117. R.J.A. Little, and D.B. Rubin Statistical Analysis with Missing Data 1987 John Wiley & Sons New York
118. D.B. Rubin Multiple Imputation for Nonresponse in Surveys 1987 John Wiley New York
119. A. Briggs, T. Clark, and J. Wolstenholme Missing... presumed at random: cost-analysis of incomplete data Health Econ 12 2003 377 392
120. J.L. Schafer Multiple imputation: a primer Stat Methods Med Res 8 1999 3 15
121. N.J. Horton, and S.R. Lipsitz Multiple imputation in practice: comparison of software packages for regression models with missing variables Am Statistician 55 2001 244 254
122. M. Raikou, and A. McGuire Estimating costs for economic evaluation A.M. Jones, The Elgar Companion to Health Economics 2006 Edward Elgar Cheltenham, UK chap 40
123. A. O'Hagan, and J.W. Stevens On estimators of medical costs with censored data J Health Econ 23 2004 615 625
124. D.Y. Lin, E.J. Feuer, and R. Etzioni Estimating medical costs from incomplete follow-up data Biometrics 53 1997 419 434
125. H. Bang, and A.A. Tsiatis Median regression with censored cost data Biometrics 58 2002 643 649
126. R.D. Etzioni, E.J. Feuer, and S.D. Sullivan On the use of survival analysis techniques to estimate medical care costs J Health Econ 18 1999 365 380
127. G.W. Carides, J.F. Heyse, and B. Iglewicz A regression based method for estimating mean treatment cost in the presence of right-censoring Biostatistics 1 2000 299 313
128. M. Raikou, and A. McGuire Estimating medical care costs under conditions of censoring J Health Econ 23 2004 443 470
129. A.A. Stinnett, and J. Mullahy Net health benefits: a new framework for the analysis of uncertainty in cost effectiveness analysis Med Decis Making 18 Suppl. 2 1998 S68 S80
130. M. Tambour, N. Zethraeus, and M. Johannesson A note on confidence intervals in cost-effectiveness analysis Int J Technol Assess Health Care 14 1998 467 471
131. A.R. Willan, and D.Y. Lin Incremental net benefit in randomized clinical trials Stat Med 20 2001 1563 1574
132. B.A. Van Hout, M.J. Al, and G.S. Gordon Costs, effects and C/E-ratios alongside a clinical trial Health Econ 3 1994 309 319
133. E. Fenwick, K. Claxton, and M. Sculpher Representing uncertainty: the role of cost-effectiveness acceptability curves Health Econ 10 2001 779 787
134. E.C. Fieller Some problems in interval estimation with discussion J Roy Stat Soc Series B 16 1954 175 188
135. A.R. Willan, and B.J. O'Brien Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem Health Econ 5 1996 297 305
136. D.F. Heitjan Fieller's theorem and net health benefits Health Econ 9 2000 327 335
137. K. Claxton Bayesian approaches to the value-of-information: implications for the regulation of new pharmaceuticals Health Econ 8 1999 269 274
138. S. Eckerman, and A.R. Willan Expected value of information and decision making in HTA Health Econ 16 2007 195 209
139. J.J. Carlson, R. Thariani, and J. Roth Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics Med Decis Making 33 2013 463 471
140. S. Griffin, N.J. Welton, and K. Claxton Exploring the research decision space: the expected value of information for sequential research designs Med Decis Making 30 2009 155 162
141. R.J. Willke, H.A. Glick, and D. Polsky Estimating country-specific cost-effectiveness from multinational clinical trials Health Econ 7 1998 481 493
142. M. Barbieri, M. Drummond, and R.J. Willke Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability Value Health 8 2005 10 23
143. B. Jönsson, and M. Weinstein Economic evaluation alongside multinational clinical trials: study considerations for GUSTO IIb Int J Technol Assess Health Care 13 1997 49 58
144. J.R. Cook, M. Drummond, and H. Glick Assessing the appropriateness of combining economic data from multinational clinical trials Stat Med 22 2003 1955 1976
145. S. Wordsworth, and A. Ludbrook Comparing costing results in across country evaluations: the use of technology specific purchasing power parity estimates Health Econ 14 2005 93 99
146. A. Bagust, and S. Beale Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach Med Decis Making 34 2014 343 351
147. K.M. Anderson, P.W.F. Wilson, and P.M. Odell An updated coronary risk profile Circulation 83 1991 356 362
148. N.R. Latimer Survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data: inconsistencies, limitations, and practical guide Med Decis Making 33 2013 743 754
149. M.D. Schleinitz, J.P. Weiss, and D.K. Owens Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Am J Med 116 2004 797 806
150. D.B. Mark, M.A. Hlatky, and R.M. Califf Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction N Engl J Med 332 1995 1418 1424
151. D.B. Mark, C.L. Nelson, and A.A. Tsiatis Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure Circulation 114 2006 135 142
152. S.D. Ramsey, K. Berry, and R. Etzioni Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema N Engl J Med 348 2003 2092 2102
153. J.J. Caro, A.H. Briggs, and U. Siebert Modeling good research practices - overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1 Value Health 15 2012 796 803
154. M. Roberts, L.B. Russell, and A.D. Paltiel Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2 Value Health 15 2012 804 811
155. U. Siebert, O. Alagoz, and A.M. Bayoumi State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3 Value Health 15 2012 812 820
156. J. Karnon, J.E. Stahl, and A. Brennan Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4 Value Health 15 2012 821 827
157. R.J. Pitman, D. Fisman, and G.S. Zaric Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5 Value Health 15 2012 828 834
158. A.H. Briggs, M.C. Weinstein, and E. Fenwick Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6 Value Health 15 2012 835 842
159. D.M. Eddy, W. Hollingworth, and J.J. Caro Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4 Value Health 15 2012 843 850
160. D. Meltzer Accounting for future costs in medical cost-effectiveness analysis J Health Econ 16 1997 33 64
161. P. O'Neill, and N.J. Devlin An analysis of NICE's 'restricted' (or 'optimized') decisions Pharmacoeconomics 28 2010 987 993
162. R.J. Willke, Z. Zheng, and P. Subedi From concepts, theory and evidence of heterogeneity of treatment effects to analytic approaches: a primer BMC Med Res Methodol 12 2012 185
163. European Medicines Agency Committee for Medicinal Products of Human Use. Guideline on the investigation of subgroups in confirmatory clinical trials (DRAFT). 2014. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/02/WC500160523.pdf. [Accessed December 19, 2014].
164. P.A. Scuffham, M.J. Yelland, and J. Nickles Are n-of-1 trials economically viable options to improve access to selected high-cost medications? Value Health 11 2008 97 109
165. P. Deb, and P.K. Trivedi The structure of demand for health care: latent class vs. two-part models J Health Econ 21 2002 601 625
166. S. Frühwirth-Schatter, R. Tüchler, and T. Otter Bayesian analysis of the heterogeneity model J Bus Econ Stat 22 2004 2 15
167. M.F. Drummond, T.O. Jefferson for the BMJ Working Party on Guidelines for Authors and Peer-Reviewers of Economic Submissions to the British Medical Journal. Guidelines for authors and peer-reviewers of economic submissions to the British Medical Journal BMJ 313 1996 275 383
168. J.E. Siegel, M.C. Weinstein, L.B. Russell, and M.R. Gold Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine JAMA 276 1996 1339 1341
169. D. Husereau, M. Drummond, and S. Petrou Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement Value Health 16 2013 e1 e5
170. D. Husereau, M. Drummond, and S. Petrou Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR Health Economic Evaluations Publication Guidelines Good Reporting Practices Task Force Value Health 16 2013 231 250
171. K.F. Schulz, D.G. Altman, and D. Moher CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152 2010 726 732